C4 Therapeutics, Inc

CCCCNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

122.9M

on 2026-06-30, from 68.8M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$400.0M

S-3 of 2025-11-21. 1 prospectus supplement filed under it since. S-3 ↗

$200.0M

TD Securities (USA), agreement of 2025-12-10. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-11 is not read yet.

Cash

3.7 quarters

$78.6M on 2026-06-30 ÷ $21.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-10-16	Public offering incl. 28.71M pre-funded, with warrants at $2.22	50,608,500	$2.47	$125.0M	424B5 ↗